# Lorigerlimab

Source: https://onco.cc/drugs/lorigerlimab/  
OnCo record `lorigerlimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lorigerlimab is an experimental bispecific antibody from MacroGenics in phase 2 trials for ovarian cancer, vulvar cancer and cervical cancer, aimed at PD-1 and CTLA-4.

## Summary

Lorigerlimab (MGD019) is a bispecific antibody developed by MacroGenics. Its targets are PD-1 and CTLA-4 (the sponsor names PD-1 x CTLA-4). The sponsor states: A DART (Dual Affinity Re-Targeting) bispecific protein that simultaneously engages the PD-1 and CTLA-4 checkpoint pathways to enhance anti-tumour immune responses. ClinicalTrials.gov describes the intervention as: Bispecific DART protein binding PD-1 and CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, vulvar cancer, cervical cancer and endometrial cancer. The largest, NCT06730347, plans to enrol 80 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: MGD019
- Modality: bispecific antibody
- Mechanism: A DART (Dual Affinity Re-Targeting) bispecific protein that simultaneously engages the PD-1 and CTLA-4 checkpoint pathways to enhance anti-tumour immune responses.

## Sources

- ClinicalTrials.gov: trials of Lorigerlimab: https://clinicaltrials.gov/search?intr=MGD019
- Sponsor pipeline page: https://macrogenics.com/pipeline/

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [MacroGenics](https://onco.cc/companies/macrogenics/)
- trials: [A Study of Lorigerlimab in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06730347/), [Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di](https://onco.cc/trials/nct07071961/)

---
JSON: https://onco.cc/api/v1/entities/lorigerlimab.json